PROTAC-Based Antivirals for Respiratory Viruses: A Novel Approach for Targeted Therapy and Vaccine Development

Area of Science:

• Virology
• Molecular Biology
• Drug Discovery

Background:

• Respiratory viral infections pose a significant global health burden due to high transmissibility and evolving antiviral resistance.
• Current antiviral drugs and vaccines have limitations against rapidly mutating viruses like influenza, SARS-CoV-2, and RSV.
• Proteolysis-targeting chimeras (PROTACs) are emerging as a novel therapeutic modality for viral infections.

Purpose of the Study:

• To review the antiviral potential of PROTACs as therapeutic agents against respiratory viruses.
• To explore the application of PROTACs as vaccine components for respiratory viral pathogens.
• To discuss the challenges and future prospects of PROTAC-based antiviral strategies.

Main Methods:

• Review of existing literature on PROTAC technology and its application in virology.
• Analysis of PROTACs targeting viral proteins (e.g., influenza HA/NA, SARS-CoV-2 spike) and host factors.
• Discussion of PROTACs for proteasome-based virus attenuation in vaccine development.

Main Results:

• PROTACs demonstrate promising antiviral mechanisms by degrading viral and host proteins essential for viral replication.
• PROTACs can be engineered to target specific viral components, offering tailored therapeutic strategies.
• PROTACs show potential for developing novel vaccines through proteasome-mediated attenuation, enhancing immune response and safety.

Conclusions:

• PROTAC technology presents a transformative approach to combatting respiratory viruses, offering new therapeutic and vaccine avenues.
• Targeting viral and host proteins with PROTACs can overcome limitations of existing treatments and vaccine strategies.
• Despite challenges like viral mutations and delivery, advanced computational design may accelerate PROTAC-based antiviral development.